Clinical Trial Update: A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating gemcitabine plus erlotinib as adjuvant therapy for resected pancreatic cancer was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Herbert J. Zeh, III MD, FACS | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-09-19